Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Centre Hospitalier Universitaire De Nantes

Verified siteinfo

France 1 Place Alexis Ricordeau, 44000 Nantes, France

  • 350 trials recruiting
  • Plasma cell myeloma · Acute myeloid leukaemia · Dermatitis atopic
  • Adults and children

About Specializations

Centre Hospitalier Universitaire De Nantes in Nantes, France specialises in clinical trials of conditions such as Plasma cell myeloma, Acute myeloid leukaemia, Dermatitis atopic, Plasma cell myeloma refractory, and other specialisations. This site conducts important research.

Main research areas of the site

Dermatology Clinical Research at Centre Hospitalier Universitaire De Nantes

The trial portfolio focuses on Skin and Connective Tissue Diseases, with research centered on atopic dermatitis and eczema. This work is aimed at improving care for people living with chronic inflammatory skin conditions.

  • Studies are evaluating new treatment approaches for moderate-to-severe atopic dermatitis.
  • Research is assessing whether adding a targeted therapy can improve symptom control compared with standard care.
  • The site contributes to pediatric and adolescent dermatology research, including studies in younger patients with eczema.

With 6 clinical trials and a large investigator base, the Nantes site supports active clinical testing in inflammatory skin disease, combining treatment evaluation with efforts to improve outcomes for patients and families.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
1 Place Alexis Ricordeau44000 NantesFrance
Open in maps ↗
Recruiting now
350 trials
Conditions studied
411
Partner status
Verified site

More sites in NantesFrance

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

803 clinical trials

Papulopustular rosacea

Recruiting

Efficacy and safety of remibrutinib (LOU064) in adult patients with papulopustular rosacea: a randomized, double‑blind, placebo‑controlled Phase 2 trial

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Asthma

Recruiting

Safety and Tolerability of Benralizumab in Patients with HES, EGPA, or Asthma Who Completed a Prior Study

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:Astrazeneca AB

Study of JNJ-78934804 (guselkumab and golimumab) versus guselkumab in adults with moderately to severely active Crohn’s disease

Recruiting
InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Chronic kidney disease

Recruiting

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:Astrazeneca AB

Chronic spontaneous urticaria

Recruiting

A study to evaluate the long-term safety and effectiveness of barzolvolimab in patients with chronic spontaneous urticaria

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.

Crohn's disease

Recruiting

A study to evaluate the effectiveness and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Crohn's disease

Recruiting

A study to evaluate the efficacy and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Psoriasis

Recruiting

Long-term safety study of deucravacitinib compared to ustekinumab in adults with moderate to severe plaque psoriasis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Colitis ulcerative

Recruiting

A study of duvakitug for patients with moderately to severely active ulcerative colitis to see if it works and is safe as maintenance therapy

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Colitis ulcerative

Recruiting

A study testing duvakitug for patients with moderately to severely active ulcerative colitis

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Colorectal cancer metastatic

Recruiting

A Study of Ivonescimab Combined with Fluorouracil, Folinic Acid, and Oxaliplatin Compared to Bevacizumab for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Summit Therapeutics Inc.

Vitiligo

Recruiting

Study of ruxolitinib cream for children aged 6 to 12 years with non-segmental vitiligo

Investigational
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Ruxolitinib
  • Sponsor:Incyte Corp.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.